Hematopoietic chimerism (HpC) was assayed monthly using a sensitive, polymerase chain reaction (PCR) -based method in consecutive patients. Between January 1998 and April 2002, 181 patients underwent non-T cell depleted allogeneic hematopoietic cell transplantation (HCT). A total of 163 patients were evaluable for HpC at 1 month (11 early deaths; no informative band for HpC analysis/no genomic DNA in seven). In all, 53 of 163 patients (33%, median recipient DNA of 15% (range 5-95)), 39 of 151 patients (26%), and 27 of 142 patients (19%) showed mixed chimerism (MC) at 1, 2, and 3 months after HCT, respectively. Conditioning regimen (busulfan-fludarabine-ATG vs BuCy, relative risk 3.99 (95% CI 1.16-10.92)), neutrophil engraftment (Xday 17 vs pday 16, relative risk 2.49 (95% CI 1.14-5.41)), and acute graft-versushost disease within 30 days (none vs yes, relative risk 4.78 (95% CI 1.50-15.17)) were independent variables that showed significant correlation with having X5% recipient DNA at 1 month. Five patients experienced secondary graft failure. All five patients showed MC at 1 month with median recipient DNA of 40%. None of the 109 patients with complete chimerism experienced graft failure (P ¼ 0.002). Our study showed that MC shown on monthly analysis of HpC after allogeneic HCT is a significant predictor of secondary graft failure.
poietic cell transplantation Assays of hematopoietic chimerism (HpC) in patients who have undergone allogeneic hematopoietic cell transplantation (HCT) may provide physicians with valuable information regarding the status of transplanted hematopoietic grafts, [1] [2] [3] [4] [5] as well as providing information about the clinical course of the patients. Several methods can be used to assay HpC. Polymerase chain reaction (PCR)-based procedures utilizing the amplification of polymorphic DNA sequences, such as short tandem repeats (STRs) or variable number of tandem repeats, are used widely because they are sensitive, require a small amount of sample, and are not dependent upon a sex mismatch. [1] [2] [3] [4] It is, however, yet to be determined how to apply these techniques in the care of patients after allogeneic HCT, especially with regard to optimal timing and scheduling of the tests, and also in the interpretation of the results.
When sensitive PCR-based methods were employed, up to half of the patients were shown to have varying proportions of recipient DNA (mixed chimerism, MC) especially early after allogeneic HCT. [3] [4] [5] [6] [7] [8] [9] It has been suggested that MC after allogeneic HCT is a marker of immune tolerance, and thus may be related to a decreased frequency of graft-versus-host disease (GVHD). [10] [11] [12] [13] There are studies that have described increased graft failure in patients with MC after allogeneic HCT. 1, 2, 10, 13 As for the relapse of leukemia, several studies have suggested that MC after allogeneic HCT was correlated with relapse in chronic myelogenous leukemia (CML). [14] [15] [16] [17] In cases of acute leukemia, the findings were not consistent among studies, with some studies suggesting a correlation of MC with relapse [18] [19] [20] [21] while others failed to show such a correlation. 6, 8, 9, 14, 17, 22 In most studies, the timing of the assay of HpC after HCT was not controlled and the data were analyzed retrospectively. 2, [9] [10] [11] [17] [18] [19] In a series of 163 consecutive adult patients who underwent allogeneic HCT in our hospital, we monitored the status of HpC using a sensitive PCR-based method at monthly intervals in a prospective manner. We conducted this study to (1) identify pre and post transplant variables that may determine the chances of having MC at 1, 2, and 3 months after allogeneic HCT, and (2) evaluate the clinical significance of having MC early after allogeneic HCT especially in terms of graft failure and relapse of leukemia.
Patients and methods

Patients and transplantation procedure
Consecutive patients who underwent allogeneic HCT at the University of Ulsan, Asan Medical Center in Seoul, Korea, beginning in January 1998, were enrolled in the study. Written informed consents for hematopoietic cell collection and transplantation were obtained from the patients and donors. Study protocols for specific conditioning regimens were approved by the Institutional Review Board. Before July 1999, all patients with malignant disorders, including myelodysplastic syndrome (MDS), received a BuCy regimen (busulfan 4 mg/kg/day orally on days À7 to À4 and cyclophosphamide 60 mg/kg/day by intravenous infusion on days À3 to À2) 23 and patients with severe aplastic anemia (SAA) received a Cy-ATG regimen (cyclophosphamide 50 mg/kg/day by intravenous infusion on days À5 to À2 and equine antithymocyte globulin (Atgam s , Upjohn, Kalamazoo, MI, USA) 30 mg/kg/day by intravenous infusion on days À4 to À2) 24 for conditioning therapy with subsequent infusion of donor marrow cells on day 0. Beginning in July 1999, a nonmyeloablative conditioning regimen of Bu-Flu-ATG (busulfan 4 mg/kg/day orally on days À7 and À6, fludarabine (Fludara s , Berlex Laboratories, Richmond, CA, USA) 30 mg/m 2 /day by intravenous infusion on days À7 to À2, Atgam s 20 mg/kg/day by intravenous infusion on days À5 to À2, and methylprednisolone 2 mg/kg/day by intravenous infusion on days À5 to À2) 25 was given to patients with acute leukemia who were elderly or who had comorbidity, patients with chemotherapy-refractory malignancies, and patients with low-risk MDS or paroxysmal nocturnal hemoglobinuria (PNH). One patient with SAA also received a Bu-Flu-ATG regimen due to poor performance status and relatively old age (47 years). HLA matching for donor selection was based on serologic typings for HLA -A, B, and C antigens (Terasaki Oriental HLA (72) Well Tray, Lot #23A, One Lambda Inc., Canoga Park, CA, USA) and a molecular typing for HLA-DRB1 antigen (LiPA HLA-DRB1, Innogenetics, Ghent, Belgium). For unrelated donors, six antigens of HLA-A, B, and DRB1 were considered. Patients who were conditioned with the Bu-Flu-ATG regimen received granulocyte colony-stimulating factormobilized peripheral blood hematopoietic cells (G-CSF, 10 mg/ kg/day subcutaneously for 4 days) on days 0 and 1. None of the hematopoietic cell grafts were T cell depleted. The regimen for the prophylaxis of GVHD consisted of cyclosporine 1.5 mg/kg by intravenous infusion every 12 h starting on day À1, then switched to an oral dose when oral intake became feasible. Cyclosporine levels were monitored weekly with a reference blood level of 100-300 ng/ml (CYCLO-Trac s SP-Whole Blood, DiaSorin, Stillwater, MN, USA). The dose of cyclosporine was reduced by 50% when the serum creatinine level exceeded twice the baseline level. Cyclosporine was discontinued if the serum creatinine level exceeded three times the baseline. In addition to cyclosporine, patients received a short course of methotrexate. The initial 19 patients who received Bu-Flu-ATG for conditioning and those who were included in a randomized trial comparing cyclosporine plus methotrexate vs cyclosporine alone for the GVHD prophylaxis and who were assigned to the cyclosporine alone arm did not receive methotrexate. All patients received a daily dose of G-CSF 450 mg intravenously starting on day 0 or 5 of infusion of donor hematopoietic cells until peripheral blood absolute neutrophil count (ANC) was over 3000/ml. The same dose of G-CSF was administered daily when ANC decreased below 1000/ml.
All patients were monitored prospectively for the occurrence of adverse events, including GVHD, regimenrelated toxicities, and infections. Acute and chronic GVHD were classified according to the criteria of Przepiorka et al 26 and Sullivan, 27 respectively. A diagnosis of veno-occlusive disease of the liver (VOD) was made according to the clinical criteria of McDonald et al. 28 The severity of VOD was classified into mild, moderate, or severe. 29 Graft failure was classified into primary (never achieving ANC over 500/ ml) and secondary (decrement of ANC below 500/ml after achieving engraftment, despite daily administration of G-CSF).
Specimens
Peripheral blood samples were obtained from the donor and the recipient before HCT. After HCT, peripheral blood samples of the recipient were drawn monthly for the first 12 months and then every 3 months for an additional 2 years or until death. Beginning in January 2000, samples were drawn monthly for the first 3 months and then every 3 months for 2 years after HCT. When a particular month's sample showed evidence of recipient DNA, samples were drawn monthly until complete chimerism (CC) was re-established. Genomic DNA was extracted from the buffy coat layer of cells using the Wizardt Genomic DNA purification kit (Promega, Madison, WI, USA).
PCR analysis
Detailed methods of PCR analysis have been described previously. 6 STRs are di-, tri-, tetra-, or pentanucleotide repeat sequences that are widely dispersed throughout the human genome. 30 The length of a PCR-amplified fragment is directly proportional to the number of repeat units present, thus allowing the identification of different individuals. A panel of nine paired primers for STR loci including CSF1PO, F13A01, FESFPS, LPL, TPOX, TH01, HPRTB, vWA, and F13B (GenePrintt STR Systems, Promega, Madison, WI, USA) was used in the initial screening process to identify the most informative STR locus in a given donor/recipient pair. Three additional primers (D16S539, D7S820, and D13S317; GenePrintt STR Systems, Promega, Madison, WI, USA) were used since March 2002. An STR locus was defined as being informative for a given donor/recipient pair if there was at least one unique band of the recipient that could be distinguished from the band(s) of the donor. Whenever possible, the STR locus in which at least one recipientspecific allele had a longer PCR-amplified fragment than those of the donor alleles was chosen to avoid misinterpretation of results by artifacts of the donor alleles. These artifacts are commonly generated and usually located at one or two repeat units below the original bands by the mechanism known as slipped mispairing in PCR amplification of STRs. 31 If an artificial band from the donor is in the same position as the recipient's unique band, then the interpretation of the results could be compromised. When there was no usable locus in the STR system, the amelogenin system was chosen in cases in which the recipient was male and the donor was female. After the screening, PCR analyses were carried out on sequential post transplant samples of the recipient using the most informative locus for each donor/recipient pair. All reactions were performed in a volume of 25 ml containing 50 mmol/l KCl, 10 mmol/l Tris-HCl (pH 9.0), 1.5 mmol/l MgCl 2 , 0.1% Triton s X-100, 200 mmol/l of each dNTP, 2.5 ml of each 10 Â primer pair (Gene Print STR Systems, Promega, Madison, WI, USA), 0.5 U of Taq polymerase (Promega, Madison, WI, USA), and 250 ng of template DNA. Following amplification, PCR products was electrophoresed on 6% polyacrylamide gel containing 7 m urea and 0.5 Â TBE. For loading, 2.5 ml of each PCR products were mixed with an equal volume of formamide loading buffer containing xylene cyanol. Before loading the samples, the gel was prerun at 40 W for 30 min to achieve a gel surface temperature of approximately 501C. After denaturing at 951C for 2 minutes, 3 ml of the each sample was loaded in the respective well and electrophoresed at 40 W until the xylene cyanol dye reached the end of plate. Following electrophoresis, silver staining was done for direct visualization. The sensitivity to detect minor cell population with the PCR assay of STRs or amelogenin loci has been shown to be in the range of 0.5-2.5% depending on the primers used. 6 
Definition and quantification of MC
If there was one or more visible band of recipient DNA, the signals of each band were analyzed densitometrically using the Gel-Doc 1000 imaging system and Multi-Analyst/PC s software (Bio-Rad, Hercules, CA, USA) for quantification of the degree of MC. The degree of MC was defined as a proportion of the recipient cell population in a given sample and determined by the proportion of the peak areas corresponding to the recipient signals as compared to the sum of peak areas of the donor and the recipient signals as described by Thiede et al. 2, 7 The value was rounded off to the nearest 5%. Those cases that showed a recipient signal of 5 to 95% were defined as MC.
Statistics and data analysis
Categorical variables were compared using a w 2 test. Percentages of recipient DNA in patients with MC were compared using the Mann-Whitney U-test. The multivariate analysis was performed with logistic regression analysis. Cumulative incidence curves for the times to secondary graft failure were plotted using the KaplanMeier method and were compared using a log-rank test. For patients with leukemia, the time to leukemia relapse was defined as the interval between HCT and the relapse of leukemia. Patients who died due to complications of HCT without a relapse of leukemia were censored at the time of death for the calculation of the time to leukemia relapse. Cumulative incidence curves for leukemia relapse were plotted using the Kaplan-Meier method and were compared using a log-rank test.
Results
Patients
Between January 1998 and April 2002, 181 patients with various malignant and nonmalignant disorders underwent allogeneic HCT. In one patient with SAA, genomic DNA was not available from the peripheral blood (no visible buffy coat layer). In six patient/donor pairs, an informative band for chimerism analysis could not be identified due to slippage artifact bands that hampered evaluation of the recipient band. A total of 11 patients, including one patient without an informative band for chimerism analysis, died within 1 month of HCT before they could be evaluated for HpC. The causes of death were VOD with sepsis (n ¼ 4), engraftment failure and sepsis (n ¼ 2), acute GVHD (n ¼ 1), CNS hemorrhage (n ¼ 1), CMV pneumonia (n ¼ 1), pulmonary hemorrhage with respiratory failure (n ¼ 1), and progression of underlying soft tissue sarcoma (n ¼ 1). One patient died 61 days after HCT of primary engraftment failure and sepsis. No genomic DNA could be obtained from the peripheral blood for an HpC assay at 1 month. Thus, the remaining 163 patients were evaluable for HpC at 1 month after HCT. The characteristics of these patients are described in Table 1 . The median age of the patients was 30 years (range 15-59). There were 97 male and 66 female patients. Diagnoses included acute myeloid leukemia (AML, n ¼ 55), acute lymphoblastic leukemia (ALL,
, and unclassified myeloproliferative disorder (n ¼ 1). Conditioning regimens included BuCy (125 patients), Cy-ATG (13 patients), and Bu-Flu-ATG (24 patients). In all, 118 patients received hematopoetic stem cells from siblings (including three patients with a one-locus mismatch) and 45 patients from unrelated donors (including eight one-locus mismatches and one two-locus mismatch); 139 patients received hematopoietic cells that were harvested from donor bone marrows; 24 patients received G-CSF-mobilized peripheral blood hematopoietic cells from HLAmatched sibling donors; 45 patients received cyclosporine alone for GVHD prophylaxis; 36, 72, eight, and two patients received four, three, two, and one doses of methotrexate, respectively, in addition to cyclosporine.
Frequencies of MC at 1, 2, and 3 months after allogeneic HCT and factors associated with MC based on univariate analysis
Of 163 evaluable patients at 1 month after HCT, 162 achieved an ANC of 500/ml or higher on median day 15.5 (range 9-28) after HCT, 33 patients (20%) developed acute GVHD between days 2 and 30 of HCT (grade I, eight; grade II, three; grade III, 16; and grade IV, six). 50 patients (31%) developed VOD between days 0 and 29 of HCT (30 mild, 17 moderate, and three severe). Assays of HpC at one month after HCT revealed that 54 of 163 evaluable patients (33%) showed varying degrees of recipient DNA, including one case that showed 100% recipient DNA (Figure 1 ). Of 53 patients who showed MC, 40 (75%) had a low degree of MC with recipient DNA of 20% or less. A total of 14 patients had recipient DNA of 25% or over. When various pre and post transplant clinical characteristics were correlated with the likelihood of having recipient DNA of 5% or over at 1 month, the conditioning regimen and presence of acute GVHD within 30 days after HCT showed significant correlation. Of 24 patients (54%) who received the nonmyeloablative conditioning regimen of Bu-Flu-ATG, 13 showed recipient DNA of 5% or over at 1 month, which is significantly higher than that of those who received the BuCy regimen (35 of 125 patients, 28%, P ¼ 0.031). Of 130 patients (39%) who did not develop acute GVHD within 30 days after HCT, 50 showed recipient DNA of 5% or over at 1 month, while only four of 33 patients (12%) who developed acute GVHD showed recipient DNA (P ¼ 0.002). Engraftment days showed marginal significance (27 of 99 patients for day 16 or sooner vs 27 of 63 patients for day 17 or later, P ¼ 0.066). Other variables including age, sex, diagnosis, disease status at HCT, donor age, source of hematopoietic cells, transplanted cell dose, GVHD prophylaxis (cyclosporine plus methotrexate vs cyclosporine alone) and presence of VOD did not show significant correlation with the likelihood of MC at 1 month.
A total of 151 patients were evaluable for HpC at 2 months after HCT. In all, 11 patients died between 1 and 2 months after HCT due to the following causes: acute GVHD (n ¼ 7), CNS bleeding (n ¼ 1), bacterial pneumonia with sepsis (n ¼ 1), idiopathic interstitial pneumonia (n ¼ 1), and progression of underlying ovarian cancer (n ¼ 1). One patient received a G-CSFmobilized donor leukocyte infusion (DLI) for primary engraftment failure before evaluation of chimerism at 2 months after HCT. Of 151 patients who were evaluable for HpC at 2 months after HCT, 49 patients developed acute GVHD by day 60 (grade 1, 19; grade 2, seven; grade 3, 17; and grade 4, six). Of 151 patients, 39 (26%) showed MC with median recipient DNA of 10% (range 5-75, Figure 1 ). In all, 22 of 54 patients (41%) who showed MC at 1 month after HCT converted to CC at 2 months. Eight of 109 patients (7%) who showed CC at 1 month after HCT converted to MC at 2 months. Development of acute GVHD by day 60 showed marginal significance for the lower frequency of MC at 2 months (P ¼ 0.057). The 
-•
-
-•
-
-• ••
-
-•
-
1 month 2 months 3 months Figure 1 Distribution of the percentage of recipient DNA in patients who showed recipient DNA of 5% or over at 1 month (54 patients), 2 months (39 patients), and 3 months (27 patients) after allogeneic HCT. The percentage of recipient DNA was determined by the proportion of the peak areas corresponding to the recipient signals as compared to the sum of peak areas of the donor and recipient signals. The value was rounded off to the nearest 5%.
conditioning regimen lost its statistical significance at 2 months (P ¼ 0.599). A total of 142 patients were evaluated for HpC at 3 months after HCT. Seven patients died between 2 and 3 months after HCT due to progression of underlying malignancies (n ¼ 3), VOD/multiorgan failure (n ¼ 2), idiopathic interstitial pneumonia (n ¼ 1), and graft failure/ sepsis (n ¼ 1). Two patients received G-CSF mobilized DLI for relapse of lymphoma and engraftment failure, respectively, before evaluation for HpC at 3 months. Of 142 evaluable patients, 48 developed acute GVHD by day 90 (grade I, 18; grade II, eight; grade III, 16; and grade IV, six). Of 142 evaluable patients, 27 (19%) showed MC at 3 months after HCT with median recipient DNA of 15% (range 5-85, Figure 1 ). In all, 13 of 39 patients (33%) who showed MC at 2 months after HCT converted to CC at 3 months. Six of 112 patients (5%) who showed CC at 2 months after HCT converted to MC at 3 months. None of the pre and post transplant variables showed a significant correlation with the likelihood of MC at 3 months.
Pre and post transplant factors associated with MC based on multivariate analysis
The variables that showed a significance level of P-value o 0.1 on univariate analysis, as well as the patient age and sex, were considered in the variable selection process: conditioning regimen (Bu-Flu-ATG vs BuCy, relative risk 3.99 (95% CI 1.16-10.92)); neutrophil engraftment day (day 17 or later vs day 16 or sooner, relative risk 2.49 (95% CI, 1.14-5.41)), and the presence of acute GVHD within 30 days after HCT (none vs yes, relative risk 4.78 (95% CI 1.50-15.17)) were independent variables that showed a significant correlation with the likelihood of having recipient DNA of 5% or over at 1 month after HCT (Table 2) . No variable showed significance for the likelihood of MC at 2 and 3 months.
MC vs graft failure after allogeneic HCT
One patient who showed 100% recipient DNA at the 1-month HpC assay was in a state of primary engraftment failure at the time of the HpC assay.
There were 15 patients who experienced decrement of ANC to below 500/ml after initially achieving engraftment without evidence of persistence or relapse of underlying disease in the bone marrow. Of these 15 patients, 10 recovered from myelosuppression 2-71 days later with daily administration of G-CSF. The etiologies of transient neutropenia in these patients were felt to be acute GVHD with concomitant administration of myelosuppressive drugs, such as mycophenolate mofetil and/or ganciclovir in seven patients; CMV infection with concomitant administration of ganciclovir in two; and splenomegaly in one. The other five patients showed secondary graft failure that was persistent despite daily administration of G-CSF. All these patients showed initial evidence of bone marrow recovery, with peripheral blood ANC ranging from 670 to 2980/ml at 1 month, but then experienced secondary graft failure with decrement of ANC to below 500/ml on days 42, 53, 60, 73, and 470. All five patients who experienced secondary graft failure showed MC at 1 month with median recipient DNA of 40% (range 25-55%). The median recipient DNA level of the 5 patients who experienced secondary graft failure was significantly higher than the median recipient DNA level of the 48 patients with MC at 1 month who did not experience graft failure (10%, range 5-95%, P ¼ 0.001). None of 109 patients who showed CC at 1 month experienced primary or secondary graft failure (P ¼ 0.002, Table 3 ).
Another variable that showed correlation with secondary graft failure was the presence of sex mismatches (2/40 vs 3/ 38 vs 0/84 for female to male vs male to female vs none, respectively, P ¼ 0.040, Table 3 ). Multivariate analysis to investigate independent variables for secondary graft failure was not feasible due to the small number of events (n ¼ 5) leaving multiple subsets without an event.
There were eight patients who showed recipient DNA ranging from 25 to 95% at 1 month after HCT, but subsequently converted to CC by 6 months without evidence of secondary graft failure. None of these eight patients had acute GVHD. Six had chronic GVHD. Hematologic engraftment has been maintained for 14.8-47.2 months in these patients.
MC vs relapse of AML
Four patients relapsed before day 120 of HCT and were excluded from the analysis, since a relapsing leukemic clone could interfere with the interpretation of the effect of early HpC on the relapse of leukemia. The median follow-up time of the surviving patients was 28.3 months (range 3.7-54.1). Nine patients relapsed between 4.9 and 23.7 months after HCT. Times to leukemia relapse were compared in terms of chimerism status at 1, 2, and 3 months. More patients with MC at 1, 2, and 3 months relapsed but the differences were not statistically significantly different (Table 4) . When we analyzed only those patients who were transplanted in the first complete remission (CR) status of their leukemia, the patients who showed MC relapsed more frequently (especially at 3 months) but the differences were not statistically significant.
MC vs relapse of ALL
One patient relapsed 2 months after HCT and was excluded from the analysis. The median follow-up time of surviving patients was 17.9 months (range 51.4-4.2). The time to leukemia relapse was not significantly different according to the HpC status at 1, 2, and 3 months (Table 4) . 
MC vs relapse of CML
Of the 28 patients with CML in our study, 21 underwent allogeneic HCT while they were in the chronic phase. Of these 21 patients, five died due to transplantation-related complications. None experienced hematologic relapse. One who showed MC at 1 month experienced cytogenetic relapse at 4.4 months after HCT.
Discussion
In our study, we used a sensitive, semiquantitative PCRbased method that utilized STRs or amelogenin loci of DNA. The assays were done on a fixed schedule of 1, 2, and 3 months after HCT and at least every 3 months subsequently in a consecutive series of patients. At least one set of suitable discriminating primers for PCR was found in 174 (97%) of 180 patients. It should be noted that the genomic DNA used in our study was obtained from the buffy coat layer of the peripheral blood of the patients that contains mixed populations of white blood cells, including granulocytes, monocytes, and lymphocytes. The pattern of HpC in different populations of white blood cells in different types of allogeneic HCT (ie T cell depleted vs non-T cell depleted or myeloablative vs non myeloablative) needs to be studied in further investigations. Establishment of donor chimerism in the hematopoietic system after allogeneic HCT is a dynamic process, where multiple pretransplant donor and patient factors as well as other post transplant factors are likely to play roles. Assays of HpC after allogeneic HCT reflect the end results of the interactions of these diverse factors. One of the most important factors favoring MC after allogeneic HCT is likely to be T cell depletion of the hematopoietic graft. In a series of patients who underwent allogeneic HCT after T cell depletion, 74-94% of patients were reported as showing MC. 9, 15 In our series of patients, no one received a T cell depleted hematopoietic graft and the frequency of MC at 1 month after allogeneic HCT was 33%. Our study showed that the intensity of the conditioning regimen, occurrence of acute GVHD, and engraftment time of neutrophils were important determinants of frequency of having recipient DNA of 5% or over at 1 month after allogeneic HCT (Table 2 ). These findings suggest that more intense conditioning, as well as a stronger graft reaction against the host, facilitate donor hematopoietic chimerism. Earlier engraftment time may allow a longer interval for the graft to react against the host to achieve full donor chimerism thus decreasing frequency of MC at 1 month, as shown in our study. In subsequent months, however, these factors lost statistical significance with an overall decrement of the frequency of MC (26 and 19% in 2 and 3 months, respectively).
Graft failure after allogeneic HCT may manifest as either the lack of initial engraftment (primary) or the development of pancytopenia after initial engraftment (secondary). Although graft failure is not a common complication of modern allogeneic HCT because of better HLA typing technique and less allosensitization during transfusion with the routine use of filters, the consequences of graft failure are serious. In our study, nine of 181 patients (5.0%) who were transplanted during the study period-or six of 163 evaluable patients (3.7%) -experienced graft failure. Our study showed that hematopoietic chimerism at 1 month after HCT had a predictive value for subsequent occurrence of secondary graft failure (Table 3) . Excluding one patient who experienced primary graft failure at 1 month, five of 53 patients (9.4%) who showed MC at 1 month experienced subsequent secondary graft failure, while none of the 109 patients who showed CC experienced secondary graft failure (P ¼ 0.002). Among 13 patients who showed MC at 1 month with recipient DNA of 25% or over, five patients experienced secondary graft failure. All of these 13 patients had evidence of marrow recovery on day 30 of HCT and the HpC assay was the only clinical parameter that could have suggested a possible impending secondary graft failure. Furthermore, our data suggest that there may be a proportionally increasing risk of graft failure as the percentage of recipient DNA increases, since none of the patients with MC at 1 month with recipient DNA less than 25% experienced subsequent graft failure.
Among other variables that were evaluated for the predictive value of secondary graft failure, the presence of sex mismatches between the donor and recipient showed increased frequency of secondary graft failure (2/40 vs 3/38 vs 0/84 for female to male vs male to female, vs none, respectively, P ¼ 0.040, Table 3 ). On the other hand, although there was a trend of increased frequency of MC in sex-mismatched HCT in our study (35% vs 41% vs 29% at 1 month, for female to male vs male to female vs none, respectively, P ¼ 0.381), it was not statistically significant. Other variables, such as conditioning regimen, engraftment time, and presence of acute GVHD, did not show statistically significant predictive value. Further studies with a larger number of patients are necessary to investigate whether the presence of MC at 1 month after allogeneic HCT is an independent predictive factor for subsequent secondary graft failure.
The potential value of HpC in the prediction of relapse of leukemia rests on the concept that MC indicates immune tolerance of the donor graft toward normal host tissues as well as leukemic cells. In cases of CML, persistent MC after allogeneic HCT is felt to be a marker for relapse. [13] [14] [15] [16] In cases of acute leukemia, there have been conflicting data regarding the association between MC and increased risk of relapse. There have been well-documented cases where acute leukemia relapsed without showing evidence of MC prior to relapse. 6 On the other hand, there have been cases where MC persisted for prolonged periods of time without evidence of the relapse of acute leukemia. 8 It is generally accepted that the relapse of acute leukemia is a rapidly occurring phenomenon and it cannot be predicted by regular assays of chimerism unless assays for HpC are performed at very short intervals. 5, 20 In some cases, MC detected shortly prior to leukemia relapse was due to an emerging leukemic clone. The presence of CC early after allogeneic HCT may suggest a relatively strong antihost (and/or leukemia) effect of the graft. On the other hand, the presence of MC may suggest a relatively weak antihost (and/or leukemia) effect. Whether the presence of MC early after allogeneic HCT is a prognostic factor affecting the subsequent relapse of acute leukemia has not been adequately studied. Our data in patients with acute leukemia showed that there is no statistically significant difference in the time to leukemia relapse according to the findings of HpC. However, there were trends of less relapse of AML in patients with CC especially at the third month of the HpC assay ( Table 4 ). The relation between HpC early after HCT and the subsequent relapse of leukemia needs to be studied further in a larger number of patients.
In conclusion, our study showed that the intensity of conditioning, presence of acute GVHD, and neutrophil engraftment time were important determinants of the presence of recipient DNA of 5% or over at 1 month after allogeneic HCT. The presence of MC at 1 month was a significant predictor of secondary graft failure. Whether an HpC assay performed sooner or later after HCT (ie 3 or 6 weeks) or performed at shorter intervals might have further predictive value needs to be determined. Whether early DLI is effective in the prevention of subsequent graft failure in patients who show a high proportion of recipient DNA on HpC assays early after allogeneic HCT also needs study.
